The number and complexity of medical-device recalls have rapidly increased, raising questions about safety and risks for hospitals that mostly still track and locate faulty products manually.
The next Ebola or the next SARS. Maybe even the next HIV. Even before the Ebola epidemic in West Africa is brought under control, public health officials are girding for the next health disaster.
The Food and Drug Administration is warning against the use of laparoscopic power morcellator devices to treat uterine fibroids, while obstetricians and gynecologists insists that some women should still have access to the products.
The private practice oncologist is becoming a vanishing breed, driven away by the changing economics of cancer medicine.
Dr. Thomas Malone, 57, will become CEO of Summa Health System, Akron, Ohio, effective Jan. 1. He is replacing CEO Tom Strauss, who will retire after 15 years in the position.
Having a child undergo surgery can be nerve-racking. So Arnold Palmer Hospital for Children in Orlando, Fla., has devised an app to help with that. EASE—which stands for Electronic Access to Surgical Events—allows patients' families and caregivers to get updates about their loved ones'...
As families gather around their tables to partake in turkey, stuffing and yams, the federal government is encouraging Americans to map out how health issues have defined their ancestry.
Earlier this year, two leaders at the National Institutes of Health said there is growing concern from scientists and laypeople that the system for ensuring the reproducibility of biomedical research “is failing and is in need of restructuring.” The NIH will address this concern Monday...
The Obama administration wants to modify policies for automatic health insurance re-enrollments and strengthen rules for provider directories for the 2016 open enrollment period.
Around the country, a number of graduate medical education programs are training doctors in community-based medicine, hoping they'll practice in underserved communities.
Merck & Co. will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine. Merck will have the right to research, develop, manufacture, and distribute the vaccine, rVSV-EBOV, as well as any follow-on products, the companies said in a joint statement.
Comment on today's news and share your opinions with other readers. Submit your letter to the Modern Physician Reader Forum at email@example.com. Submissions must include name, title, affiliation, city and state. Modern Physician reserves the right to edit all...